Comparative economic evaluation of Haemophilus influenzae type b vaccination in Belarus and Uzbekistan

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Griffiths, Ulla K ^a   Clark, Andrew ^a   Shimanovich, Veronika ^b   Glinskaya, Irina ^c   Tursunova, Dilorom ^d   Kim, Lucia ^d   Mosina, Liudmila ^e   Hajjeh, Rana ^f   Edmond, Karen ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Dept of Infect Dis Contr and I   (Belarus)

^c Minsk City Centre for Hygiene and Epidemiology   (Belarus)

^d Ministry of Health Uzbekistan   (Uzbekistan)

^e WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE VACCINE; HAEMOPHILUS VACCINE;

ARTICLE; BELARUS; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS MENINGITIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; INFLUENZA B; INFLUENZA VACCINATION; LIVE BIRTH; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STREPTOCOCCUS PNEUMONIA; UZBEKISTAN; BACTERIAL MEMBRANE; COHORT ANALYSIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; HEALTH SURVEY; IMMUNOLOGY; SENSITIVITY AND SPECIFICITY; VACCINATION;

HAEMOPHILUS INFLUENZAE SEROTYPE B;

BACTERIAL CAPSULES; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HAEMOPHILUS VACCINES; HEALTH STATUS INDICATORS; HUMANS; MENINGITIS, HAEMOPHILUS; REPUBLIC OF BELARUS; SENSITIVITY AND SPECIFICITY; UZBEKISTAN; VACCINATION;

EID: 79959623201     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021472     Document Type: Article

References (46)

1. Makela PH, Takala AK, Peltola H, Eskola J, (1992) Epidemiology of invasive Haemophilus influenzae type b disease. J Infect Dis 165 (Suppl 1): S2-6.
2. Edmond K, Clark A, Korczak V, Sanderson C, Griffiths U, et al. (2010) Global and regional risks of disabling sequelae from bacterial meningitis. Lancet Infectious Diseases 10: 317-328.
3. Peltola H, Salo E, Saxen H, (2005) Incidence of Haemophilus influenzae type b meningitis during 18 years of vaccine use: observational study using routine hospital data. BMJ (Clinical research ed) 330: 18-19.
4. CDC (2002) Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998-2000. MMWR Morb Mortal Wkly (2002) Rep 51: 234-237.
5. Ojo LR, O'Loughlin RE, Cohen AL, Loo JD, Edmond KM, et al. (2010) Global use of Haemophilus influenzae type b conjugate vaccine. Vaccine 28: 7117-7122.
6. Watt JP, Wolfson LJ, O'Brien KL, Henkle E, Deloria-Knoll M, et al. (2009) Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 374: 903-911.
7. Wolfson L, O'Brien KL, Watt JP, Henkle E, Deloria-Knoll MD, et al. (2009) Methods to estimate the global burden of disease due to Haemophilus influenzae type b and Streptococcus pneumoniae in children less than 5 years of age. Lancet Web annex pp. 893-902.
8. WHO (2008) WHO guide for standardization of economic evaluations of immunization programmes; Immunization, Vaccines and Biologiocals Department, Geneva, WHO/IVB/08.14.
9. Unicef and UNFPA (2006) Uzbekistan. Multiple Indicator Cluster Survey http://www.childinfo.org/files/MICS3_Uzbekistan_FinalReport_2006_Eng.pdf.
10. Balabanova D, McKee M, Pomerleau J, Rose R, Haerpfer C, (2004) Health service utilization in the former soviet union: evidence from eight countries. Health Serv Res 39: 1927-1950.
11. Richardson E, Boerma W, Malakhova I, Rusovich V, Fomenko A, (2008) Belarus: Health system review. European Observatory on Health Systems and Policies.
12. Glinskaya INGF, Chistenko GN, Fissenko EG, Levshina NN, Ushakevich IG, et al. (2008) Features of Hib infection epidemic process in Minsk City before immunization. 2nd Russian Conference on Actual Problems of Meningococcal Infection and Purulent Meningitis, October 20-21;.
13. Mager INFE, Germanovich FA, Volossar LA, Simanovich TN, (2005) Outcomes of Hib-meningitis incidence study and outlooks for immunoprophylaxis. Epidemiology and Infectious Diseases Magazine 3.
14. WHO (2001) Estimating the local burden of Haemophilus influenzae type b (Hib) disease preventable by vaccination. A rapid assessment tool Geneva WHO/V&B/01.27.
15. Mendsaikhan J, Watt JP, Mansoor O, Suvdmaa N, Edmond K, et al. (2009) Childhood bacterial meningitis in Ulaanbaatar, Mongolia, 2002-2004. Clin Infect Dis 48 (Suppl 2): S141-146.
16. Kasimova R, (2007) Comparative Study of PCR and Bacteriological Method in the Diagnostics of Meningitis. Journal Doctor 2.
17. United Nations Population Secretariat (2008) World Population Prospects: The 2008 Revision Population database.
18. Cherian T, (2005) Describing the epidemiology and aetiology of bacterial pneumonia in children: an unresolved problem. J Health Popul Nutr 23: 1-5.
19. Kojouharova M, Gatcheva N, Setchanova L, Robertson SE, Wenger JD, (2002) Epidemiology of meningitis due to Haemophilus influenzae type b in children in Bulgaria: a prospective, population-based surveillance study. Bull World Health Organ 80: 690-695.
20. Lebedova V, Krizova P, (2003) The 2001 serological survey in the Czech Republic--Hib invasive disease Haemophilus influenzae b. 11 (Suppl) Cent Eur J Public Health: S25-30.
21. Booy R, Hodgson SA, Slack MP, Anderson EC, Mayon-White RT, et al. (1993) Invasive Haemophilus influenzae type b disease in the Oxford region (1985-91). Arch Dis Child 69: 225-228.
22. Reinert P, Liwartowski A, Dabernat H, Guyot C, Boucher J, et al. (1993) Epidemiology of Haemophilus influenzae type b disease in France. Vaccine 11 (Suppl 1): S38-42.
23. Thomas K, Lalitha MK, Steinhoff, (2002) Are Haemophilus influenzae infections a significant problem in India? A prospective study and review. Clin Infect Dis 34: 949-957.
24. Akumu AO, English M, Scott JA, Griffiths UK, (2007) Economic evaluation of delivering Haemophilus influenzae type b vaccine in routine immunization services in Kenya. Bull World Health Organ 85: 511-518.
25. Murray CJL, Lopez ADe, (1996) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston Harvard School of Public Health.
26. Platonov AE, Griffiths UK, Voeykova MV, Platonova OV, Shakhanina IL, et al. (2006) Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation. Vaccine 24: 2367-2376.
27. WHO (2010) CHOosing Interventions that are Cost Effective (WHO-CHOICE) http://www.who.int/choice/en/.
28. WHO,(2006) WHO position paper on Haemophilus influenzae type b conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record. Wkly Epidemiol Rec 81: 445-452.
29. UNICEF (2010) Product menu for vaccines supplied by Unicef for the GAVI Alliance. http://www.unicef.org/supply/files/Product_Menu_Nov_2010_Published.pdf.
30. WHO (2010) WHO Vaccine Preventable Diseases Monitoring System. 2010 Global Summary Geneva WHO http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileresult.cfm.
31. Obonyo CO, Lau J, (2006) Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis. Eur J Clin Microbiol Infect Dis 25: 90-97.
32. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, et al. (1997) Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 349: 1191-1197.
33. Kim SY, Goldie SJ, (2008) Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 26: 191-215.
34. Theodoratou E, Johnson S, Jhass A, Madhi SA, Clark A, et al. (2010) The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality. Int J Epidemiol 39 (Suppl 1): i172-185.
35. WHO (2000) Introduction of Haemophilus influenzae type b vaccine into immunization programmes. Management guidelines, including information for health workers and parents WHO/V&B/00.05.
36. Bennett JV, Platonov AE, Slack MPE, Mala P, Burton AH, et al. (2002) Haemophilus influenzae type b (Hib) meningitis in the pre-vaccine era: a global review of incidence, age distributions, and case-fatality rates. Geneva WHO WHO/V&B/02.18.
37. Word Bank (2011) GDP per capita (current US$). http://data.worldbank.org/indicator/NY.GDP.PCAP.CD Accessed 21st February 2011.
38. WHO (2011) Cost-effectiveness thresholds. http://www.who.int/choice/costs/CER_thresholds/en/index.html.
39. Isakbaeva ET, Musabaev E, Antil L, Rheingans R, Juraev R, et al. (2007) Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 25: 373-380.
40. Griffiths UK, Miners A, (2009) Economic evaluations of Haemophilus influenzae type b vaccine: systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res 9: 333-346.
41. Livartowski A, Boucher J, Detournay B, Reinert P, (1996) Cost-effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in France. Vaccine 14: 495-500.
42. Garpenholt O, Silfverdal SA, Levin LA, (1998) Economic evaluation of general childhood vaccination against Haemophilus influenzae type b in Sweden. Scand J Infect Dis 30: 5-10.
43. Trollfors B, (1994) Cost-benefit analysis of general vaccination against Haemophilus influenzae type b in Sweden. Scand J Infect Dis 26: 611-614.
44. Zhou F, Bisgard KM, Yusuf HR, Deuson RR, Bath SK, et al. (2002) Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics 110: 653-661.
45. World Bank, (2011) World Development Indicators. World Bank.
46. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, et al. (2010) Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375: 1969-1987.